- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01404234
Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways (PALS)
Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa (PA) in the Lower Airways
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France
- C.H.U de Bordeaux
-
Lisieux, France
- Centre Hospitalier Robert Bissons
-
Paris Cedex 15, France
- Hôpital Necker Enfants Malades
-
-
-
-
-
Berlin, Germany
- Charite Campus Virchow Klinikum
-
Bochum, Germany
- Universitatsklinik St. Josef-Hospital
-
Erlandgen, Germany
- Kinder und Jugendklinik, Abteilung Lungen Bronchialheikunde
-
Essen, Germany
- Universitätsklinikum Essen
-
Frankfurt, Germany
- J.W. Goethe University Hopsital
-
-
-
-
-
Catania, Italy
- Azienda Ospedaliero Universitaria - Policlinico di Catania
-
Florence, Italy
- A. Meyer Children Hospital Florence
-
Verona, Italy
- Azienda Ospedaliera Instituti Ospitalieri di Verona
-
-
-
-
-
Gdansk, Poland
- Specjalistyczny Zespot Opieki Zdrowotnej nad Matka i Dzieckiem
-
Rabka Zdroj, Poland
- Instytut Gruzlicy i Chorob Pluc
-
Warszawa, Poland
- Instytut Matki i Dziecka
-
-
-
-
-
Barcelona, Spain
- Pediatric Pneunmonology and Cystic Fibrosis Clinic
-
Madrid, Spain
- Hospital Ramon y Cajal
-
Madrid, Spain
- Hospital Infantil Universitario Niño Jesús
-
Madrid, Spain
- Hospital Infantil La Paz
-
Malaga, Spain
- Hosp. Mat-Inf. Carlos Haya
-
-
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- The Children's Hospital - Denver
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Nemours Children's Clinic - Jacksonville
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Children's Memorial Hospital
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Children's Mercy Hospital & Clinics
-
-
New York
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Diagnosis of CF as determined by the 1997 CF Consensus Conference criteria:
- Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test OR
- Abnormal nasal transepithelial potential difference (NPD) test OR
- A genotype with 2 identifiable mutations consistent with CF AND
- One or more clinical features consistent with CF.
- Documented positive lower respiratory tract culture for PA at the screening visit plus two documented positive lower respiratory tract cultures for PA within 12 months prior to study entry (must have been a minimum 3 months apart.)
- Clinically stable with no evidence of significant respiratory symptoms or, if obtained for clinical evaluation, no chest radiograph findings at screening that would have required administration of IV antipseudomonal antibiotics, oxygen supplementation, or hospitalization.
Exclusion Criteria:
- Use of IV or inhaled antipseudomonal antibiotics within 14 days of study entry
- Presence of a condition or abnormality that would have compromised the participant's safety or the quality of study data, in the opinion of the investigator
- History of sputum or throat swab culture yielding Burkholderia spp. within 2 years prior to screening visit
- History of hypersensitivity/adverse reaction to aztreonam
- History of hypersensitivity/adverse reaction to beta-agonists
- History of lung transplantation
- Administration of any investigational drug or device within 30 days prior to screening visit or within 6 half-lives of the investigational drug (whichever was longer)
- Hospitalization for pulmonary-related illness within 28 days prior to screening visit
- Changes in or initiation of chronic azithromycin treatment within 28 days prior to screening visit
- Changes in or initiation of hypertonic saline treatment within 7 days prior to screening visit; for subjects on a stable regimen of hypertonic saline (28 days on/28 days off), beginning or ending a cycle of hypertonic saline was allowed
- Changes in antimicrobial, bronchodilator (BD), corticosteroid or dornase alfa medications within 7 days prior to screening visit;
- Changes in physiotherapy technique or schedule within 7 days prior to screening visit
- Abnormal renal or hepatic function results at most recent test within the previous 90 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Open-label AZLI
Participants received three 28-day courses of AZLI, each followed by 28 days off-treatment.
|
AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Discontinued Study Drug Due to Safety or Tolerability Reasons
Time Frame: Baseline to Day 168
|
Participants who discontinued study drug due to safety or tolerability reasons were defined as those with "Adverse Event (AE)/Safety or Tolerability" on the Study Drug Completion electronic case report form as the reason for early discontinuation.
The 95% confidence interval (CI) was calculated using the exact binomial method.
|
Baseline to Day 168
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in FEV1 % Predicted in Subjects Aged ≥ 6 Years
Time Frame: Baseline to Day 28, 84, and 140
|
The change in FEV1 % predicted was assessed at the end of each 28-day AZLI treatment course. FEV1 % predicted is defined as FEV1 of the patient divided by the average FEV1 in the population for any person of similar age, sex, race, and body composition. |
Baseline to Day 28, 84, and 140
|
Change From Baseline in CFQ-R Respiratory Symptoms Scale (RSS) Score in Subjects Aged ≥ 6 Years
Time Frame: Baseline to Day 28, 84, and 140
|
The change in CFQ-R RSS score was assessed at the end of each 28-day AZLI treatment course. The range of scores (units) was 0 to 100 with higher scores indicating fewer symptoms. |
Baseline to Day 28, 84, and 140
|
Change in Pseudomonas Aeruginosa (PA) Sputum Density
Time Frame: Baseline to Day 28, 84, and 140
|
The change in PA sputum density (log10 colony-forming units per gram [cfu/g]) was assessed at the end of each 28-day AZLI treatment course.
|
Baseline to Day 28, 84, and 140
|
Percentage of Participants Who Used Additional (Non-study) Antipseudomonal Antibiotics
Time Frame: Baseline to Day 168
|
The percentage of participants who used additional (non-study) antipseudomonal antibiotics (IV, inhaled, oral, IV/inhaled, IV/inhaled/oral) was summarized (number and percent) for all subjects.
|
Baseline to Day 168
|
Percentage of Participants Hospitalized at Least Once Due to a Respiratory Event
Time Frame: Baseline to Day 168
|
Baseline to Day 168
|
|
Number of Days Participants Were Hospitalized Due to a Respiratory Event
Time Frame: Baseline to Day 168
|
The average number of days hospitalized due to a respiratory event, among the 11 participants who were hospitalized for respiratory event, was reported.
|
Baseline to Day 168
|
Percentage of Participants With Pulmonary Exacerbations
Time Frame: Baseline to Day 168
|
Pulmonary exacerbations were defined as respiratory hospitalizations or discrete courses of non-study IV/inhaled antipseudomonal antibiotics.
Use of oral antibiotics alone for respiratory signs or symptoms was considered to be representative of milder clinical events and, therefore, was not included in the definition of pulmonary exacerbations.
|
Baseline to Day 168
|
Time to Pulmonary Exacerbation
Time Frame: Baseline to Day 168
|
The median days to first pulmonary exacerbation was summarized using Kaplan-Meier (KM) summary statistics.
|
Baseline to Day 168
|
Percentage of Participants With Study-drug Induced Bronchospasm
Time Frame: Pretreatment at Baseline to 30 minutes following treatment
|
Study-drug induced bronchospasm (airway reactivity) was assessed at the baseline visit as the percent change in FEV1 from the pretreatment measurement to 30 minutes following treatment for subjects ≥ 6 years or as from the Investigator's assessment for subjects < 6 years.
|
Pretreatment at Baseline to 30 minutes following treatment
|
Adverse Event Rates Adjusted for Study Duration
Time Frame: Baseline to Day 168
|
Adverse events occurring in ≥ 5% of participants adjusted for study duration were summarized.
The adjustment was made by using a standardized rate calculated as the sum of study duration across patients divided by 28 for the total number of patient months.
Rate calculations presented are the number of adverse events (AEs) per patient month.
|
Baseline to Day 168
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Infections
- Respiratory Tract Diseases
- Lung Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Pancreatic Diseases
- Fibrosis
- Cystic Fibrosis
- Pseudomonas Infections
Other Study ID Numbers
- GS-US-205-0160
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on AZLI
-
Gilead SciencesCompleted
-
Gilead SciencesCompletedBronchiectasisUnited States, Belgium, Spain, Canada, Australia, Germany, United Kingdom, Netherlands, France, Italy
-
Gilead SciencesCompletedBronchiectasisUnited States, Canada, Australia
-
Gilead SciencesCompleted
-
Gilead SciencesCovance; ClinPhone, Inc.; Chiltern International Inc.CompletedCystic FibrosisBelgium, France, Germany, Italy, Netherlands, Spain, United States, Ireland, United Kingdom, Portugal, Austria, Denmark, Switzerland
-
Gilead SciencesCompletedCystic Fibrosis | Burkholderia InfectionsUnited States, Canada
-
Gilead SciencesTerminatedCystic Fibrosis | Pseudomonas Aeruginosa Respiratory Tract Infection/ColonizationUnited States, Spain, United Kingdom, Denmark, Belgium, France, Italy, Germany, Israel, Netherlands, Austria, Greece
-
Gilead SciencesCompletedBronchiectasisUnited States
-
Gilead SciencesCompletedCystic FibrosisUnited States, Canada, Australia, New Zealand
-
Liverpool Heart and Chest Hospital NHS Foundation...University of LiverpoolCompletedCystic Fibrosis | Infection | PseudomonasUnited Kingdom